ABSI: Reports Interim Phase 1 Data
Absci reports interim phase 1 data from its trial of ABS-201, an investigational anti-prolactin receptor antibody, showing favorable safety data.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.